The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.

Autor: Parkinson JF; Cerebral Tumour Research Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, Australia. jparkinson@med.usyd.edu.au, Afaghi V, Payne CA, Buckland ME, Brewer JM, Biggs MT, Little NS, Wheeler HR, Cook RJ, McDonald KL
Jazyk: angličtina
Zdroj: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2011 Mar; Vol. 18 (3), pp. 329-33. Date of Electronic Publication: 2011 Jan 17.
DOI: 10.1016/j.jocn.2010.07.101
Abstrakt: The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs. 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p=0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs. 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.
(Copyright © 2010 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: